Silence Therapeutics Highlights its R&D Pipeline and Initiates Dose Escalation Studies for SLN360

 Silence Therapeutics Highlights its R&D Pipeline and Initiates Dose Escalation Studies for SLN360

Silence Therapeutics Highlights its Pipeline Portfolio and Provides Research and Development Update

Shots:

  • The company highlights its lead candidate, SLN360 for CV disease associated with high Lp (a) levels and has received the US FDA’s IND approval to start dose-escalation studies in healthy volunteers and secondary prevention patients with elevated Lp(a). The company plans to start dosing healthy volunteers in the P-I study later this year
  • The company reveals that it has initiated a P-I study of SLN124 in 24 healthy volunteers for beta-thalassemia and MDS, marking the first dose of a Silence’s siRNA therapeutic delivered to humans using the GalNAc-siRNA platform. SLN124 has received the US FDA’s & EMA’s ODD for adult beta-thalassemia and FDA’s ODD for MDS and RPD for beta-thalassemia
  • Silence received $2M milestones for commencing its work on the second target being explored under its complement pathway RNAi collaboration with Mallinckrodt and is eligible to receive additional $2M milestones if work commences on a third target in the collaboration

Click here ­to­ read full press release/ article | Ref: Silence Therapeutics | Image: The Pharma Letter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post